Kisspeptin-10 — Research Overview
Chemical Name: Kisspeptin-10 (KP-10) Also Known As: KP-10, metastin (45-54), kisspeptin decapeptide, C-terminal kisspeptin fragment Sequence: The conserved 10 amino acid C-terminal sequence of kisspeptin-54, which is the minimal bioactive fragment retaining full GPR54 (KISS1R) agonist activity Gene: KISS1 gene — encodes a 145-amino acid prepropeptide precursor that is proteolytically cleaved into several bioactive fragments: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. All isoforms share the identical C-terminal 10 amino acid sequence that constitutes the receptor-binding domain. Receptor: KISS1R (also known as GPR54, AXOR12, hOT7T175) — a seven-transmembrane G-protein coupled receptor expressed in GnRH neurons of the hypothalamus, anterior pituitary gonadotrophs, and multiple peripheral tissues including the placenta, pancreas, and gonads Historical Origin — An Unexpected Discovery: The KISS1 gene was first identified in 1996 at Pennsylvania State University (in Hershey, Pennsylvania — from which the “KISS” name derives, a reference to Hershey’s chocolates rather than any reproductive function) as a metastasis suppressor gene in melanoma and breast cancer cell lines. The protein product was named metastin for its ability to suppress tumor cell metastasis without affecting primary tumor growth. The reproductive role of kisspeptin was entirely unanticipated at the time of discovery and was not revealed until 2003, when two independent research groups simultaneously published that loss-of-function mutations in GPR54 cause hypogonadotropic hypogonadism in humans. Category: Endogenous neuropeptide / hypothalamic reproductive regulator / GPR54 agonist / KNDy pathway component / reproductive endocrinology research tool
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Kisspeptin-10?
Kisspeptin-10 is the shortest biologically active fragment of the kisspeptin neuropeptide family — a 10-amino acid decapeptide comprising the conserved C-terminal sequence of kisspeptin-54 that is sufficient for full activation of the KISS1R/GPR54 receptor. Despite containing only 10 amino acids compared to kisspeptin-54’s 54, kisspeptin-10 retains the complete receptor-binding and agonist activity of the larger isoforms, making it the most synthetically accessible and most commonly used kisspeptin variant in research settings. Its smaller molecular size makes it easier and less expensive to synthesize at research purity than kisspeptin-54, which has substantially expanded its utility as a pharmacological research tool.
The scientific significance of kisspeptin-10 and the kisspeptin family cannot be overstated in the context of reproductive neuroendocrinology. Before the discovery of kisspeptin’s role in 2003, a fundamental question in reproductive biology had remained unanswered for decades: what is the upstream neuronal signal that drives pulsatile GnRH release from the hypothalamus — the defining hormonal event that initiates puberty and sustains adult reproductive function? Kisspeptin, acting through GnRH neurons that uniformly express KISS1R, turned out to be the long-sought answer to this question. Kisspeptin signaling is now understood to be the principal upstream regulator of GnRH pulsatility, integrating metabolic, endocrine, and environmental signals into the reproductive hormone cascade.
The pathway from KISS1 gene product to reproductive regulation is itself an unexpectedly elegant biological story. Kisspeptin was identified as a cancer metastasis suppressor, studied for years in that context, and only through the genetic investigation of patients with unexplained failure to undergo puberty was its fundamental role in reproduction revealed — a reminder that biological roles of endogenous molecules frequently exceed their initial characterization.
The KNDy Neuron System — The Pulse Generator
Understanding kisspeptin-10’s research significance requires understanding its position within the KNDy neuron system — the hypothalamic neuronal population now recognized as the GnRH pulse generator.
KNDy neurons are specialized hypothalamic neurons in the arcuate nucleus (ARC) that co-express three neuropeptides simultaneously: Kisspeptin, Neurokinin B (NKB), and Dynorphin (Dyn) — from which the KNDy acronym derives. These three neuropeptides function as a coordinated intraneuronal autoregulatory circuit that drives the pulsatile output of GnRH. Within the KNDy circuit, NKB acts as an excitatory input (driving kisspeptin release), dynorphin acts as an inhibitory brake (terminating each kisspeptin pulse), and kisspeptin is the output signal that directly contacts and activates GnRH neurons through KISS1R.
This KNDy circuit generates the rhythmic pulsatile kisspeptin output that drives the corresponding pulsatile GnRH release — the fundamental signal that drives pulsatile LH and FSH secretion from the pituitary, which in turn drives gonadal steroid production and gametogenesis. The discovery of the KNDy pulse generator represented one of the most significant advances in reproductive neuroendocrinology in decades and established kisspeptin-10 and its larger isoforms as essential tools for studying this system.
A second, anatomically distinct population of kisspeptin neurons resides in the anteroventral periventricular nucleus (AVPV) of the hypothalamus. Unlike ARC kisspeptin neurons which respond to estrogen with negative feedback (reducing GnRH pulse frequency as estrogen rises), AVPV kisspeptin neurons respond to estrogen with positive feedback — mediating the estradiol-induced pre-ovulatory LH surge that triggers ovulation. This dual kisspeptin neuron population (ARC for negative feedback/pulsatility, AVPV for positive feedback/ovulatory surge) provides the substrate for the complete reproductive hormone cycle in females.
Mechanism of Action
KISS1R binding and Gq/11 signaling: Kisspeptin-10 binds KISS1R with high affinity, activating Gq/11-coupled intracellular signaling. Receptor activation engages phospholipase C, generating inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, and DAG activates protein kinase C. This calcium-dependent cascade drives GnRH neuron depolarization and GnRH vesicle release into the hypothalamo-pituitary portal circulation. Secondary signaling through ERK1/2 and p38 MAPK phosphorylation contributes to longer-term transcriptional effects on reproductive gene expression.
GnRH neuron activation: Virtually all hypothalamic GnRH neurons express KISS1R. Kisspeptin binding directly depolarizes GnRH neurons and triggers GnRH release — establishing kisspeptin as the most direct known upstream activator of GnRH neurons. This directness is mechanistically unusual: most inputs to GnRH neurons are indirect, operating through interneurons. Kisspeptin’s direct GnRH neuron engagement makes it uniquely powerful as a reproductive axis activator.
GnRH-dependent downstream cascade: The GnRH released by kisspeptin stimulation drives pulsatile LH and FSH secretion from pituitary gonadotrophs. LH stimulates gonadal testosterone production in males (Leydig cells) and drives follicular development and ovulation in females (theca cells, granulosa cells). FSH stimulates spermatogenesis (Sertoli cells) and folliculogenesis (granulosa cells). The full downstream hormonal cascade from kisspeptin-10 is therefore: kisspeptin-10 → GnRH → LH + FSH → gonadal sex steroids + gametogenesis.
Sex steroid feedback integration: Kisspeptin neurons are the primary site where sex steroid feedback is integrated into GnRH pulsatility regulation. Estrogen and testosterone suppress ARC kisspeptin output through negative feedback, reducing GnRH pulse frequency as gonadal steroids rise — the classic feedback loop of the HPG axis. This feedback mechanism positions kisspeptin neurons as the master integrators of peripheral gonadal hormone signals into the central reproductive axis, modulating GnRH pulsatility in response to the hormonal environment.
Desensitization with continuous exposure: Like GnRH receptor desensitization with continuous GnRH agonist administration, continuous kisspeptin exposure produces GPR54 desensitization and paradoxical suppression of LH levels. This is mechanistically important for research protocol design — pulsatile kisspeptin delivery restores physiological GnRH pulsatility, while continuous infusion at supraphysiological concentrations can suppress the HPG axis. This property also suggests potential therapeutic applications for kisspeptin analogs in conditions requiring reproductive axis suppression.
Published Research
Study 1 — Landmark Genetic Evidence: GPR54 Mutations Cause Hypogonadotropic Hypogonadism and Define Kisspeptin as Obligate for Puberty
Authors: Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr et al. (Massachusetts General Hospital / University of Cambridge) Year: 2003 Journal: New England Journal of Medicine PMID: 14573733 Full text: https://www.nejm.org/doi/full/10.1056/NEJMoa035322
This landmark New England Journal of Medicine publication (one of two simultaneous 2003 papers establishing kisspeptin as the master reproductive regulator — the parallel paper from de Roux et al. was published in PNAS) established GPR54/KISS1R as an obligate regulator of human puberty and reproductive function through genetic evidence in patients with idiopathic hypogonadotropic hypogonadism.
The authors identified inactivating point mutations and deletions in GPR54 in patients with idiopathic hypogonadotropic hypogonadism — a condition characterized by failure to undergo puberty, absence of pubertal development, low sex steroids, and low gonadotropin levels despite apparently intact pituitary anatomy.
Kiss1r knockout mice displayed a virtually identical phenotype to the human patients — hypogonadotropic hypogonadism, absent puberty, immature reproductive organs, and infertility — confirming that GPR54 function is conserved across mammalian species and is not dispensable for reproductive maturation.
The hypogonadotropic state in both human patients and mouse models was corrected by exogenous GnRH administration, confirming that the lesion is hypothalamic (upstream of the pituitary) and that kisspeptin signaling is required for normal GnRH secretion rather than for pituitary or gonadal function per se.
The authors concluded that these observations establish GPR54 as a key regulator of the biology of puberty — positioning kisspeptin and its receptor as the most upstream identified regulators of human reproductive maturation and establishing the research framework for all subsequent kisspeptin biology.
Study 2 — First Human Pharmacology: Kisspeptin-10 Stimulates Gonadotropin Release with Sexual Dimorphism
Authors: Dhillo WS, Chaudhri OB, Thompson EL et al. (Imperial College London) Year: 2007 Journal: Journal of Clinical Endocrinology and Metabolism (PMC) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3232613/
This study was among the first systematic characterizations of kisspeptin-10’s pharmacological effects in human subjects, and importantly identified a striking sexual dimorphism in the gonadotropin response that has significant implications for research protocol design.
In healthy men, serum LH and FSH were elevated after intravenous bolus kisspeptin-10 at doses as low as 0.3 and 1.0 nmol/kg respectively, confirming that kisspeptin-10 activates the HPG axis in the human male at pharmacologically tractable doses.
In healthy women during the follicular phase of the menstrual cycle, no alterations in serum gonadotropins were observed after intravenous bolus, subcutaneous bolus, or intravenous infusion of kisspeptin-10 at maximal doses studied — a striking finding demonstrating that the follicular phase estrogen environment renders the kisspeptin axis unresponsive to KP-10 in women at these doses and routes.
In women during the preovulatory phase (when estrogen positive feedback is active), serum LH and FSH were elevated after intravenous bolus kisspeptin-10 at 10 nmol/kg — demonstrating that the positive estrogen feedback state restores kisspeptin-10 responsiveness and that kisspeptin-10 can activate the preovulatory LH surge pathway.
The authors concluded that kisspeptin-10 stimulates gonadotropin release in men and in women during the preovulatory phase but fails to stimulate gonadotropin release in women during the follicular phase — with important implications for the clinical therapeutic use of kisspeptin-10 across the menstrual cycle.
Study 3 — Direct Human Comparison: Kisspeptin-10 vs Kisspeptin-54 vs GnRH in Healthy Men
Authors: Jayasena CN, Nijher G, Abbara A et al. (Imperial College London) Year: 2015 Journal: Human Reproduction (PMC) PMID: 26089302 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4507333/
This study provided the first direct head-to-head human pharmacological comparison between kisspeptin-10, kisspeptin-54, and GnRH for gonadotropin stimulation — directly characterizing the relative potency of the 10-amino acid fragment compared to the full-length isoform and the direct receptor agonist GnRH.
Healthy men received intravenous infusions of kisspeptin-10, kisspeptin-54, and GnRH at doses of 0.1, 0.3, and 1.0 nmol/kg/h in a crossover design.
Serum LH levels were approximately 3-fold higher during GnRH infusion compared with kisspeptin-10, and approximately 2-fold higher compared with kisspeptin-54 — establishing that kisspeptin-54 produces greater LH stimulation than kisspeptin-10 at equivalent molar doses, while both produce less direct LH elevation than equimolar GnRH.
The authors interpreted the lower relative potency of kisspeptin versus GnRH not as a pharmacological disadvantage but as a potential therapeutic advantage — suggesting that kisspeptin may stimulate gonadotrophins in a more physiological manner compared with current GnRH-based therapies, by acting upstream through the endogenous GnRH release pathway rather than directly driving pituitary gonadotrophs.
The study concluded that kisspeptin offers a novel means of stimulating the reproductive axis and that kisspeptin may be a valuable therapeutic candidate particularly in conditions where physiological, pulsatile reproductive axis stimulation is preferred over the more potent but less physiological direct GnRH receptor agonism.
Study 4 — Kisspeptin-54 as IVF Trigger: Proof of Concept for Oocyte Maturation with Reduced OHSS Risk
Authors: Jayasena CN, Abbara A, Comninos AN et al. (Imperial College London) Year: 2014 Journal: Journal of Clinical Investigation (PMC) Referenced via: PMC4109534
This proof-of-concept study directly evaluated kisspeptin-54 as a trigger for final oocyte maturation in IVF — one of the most clinically significant translational applications of kisspeptin biology, motivated by the major safety limitation of hCG (the standard oocyte maturation trigger) in causing ovarian hyperstimulation syndrome (OHSS).
OHSS is a potentially life-threatening complication of ovarian stimulation for IVF, driven by excessive LH receptor stimulation from exogenous hCG. Because hCG has a very long half-life of approximately 36 hours compared to endogenous LH’s much shorter duration, hCG produces prolonged LH receptor activation that drives the excessive follicular steroidogenesis and vascular permeability characteristic of OHSS.
Kisspeptin-54 administered as an IVF trigger stimulates an endogenous LH surge through the physiological hypothalamic-pituitary pathway — producing an LH elevation of normal physiological duration rather than the prolonged supraphysiological hCG-driven LH receptor stimulation. This mechanistic difference is the basis for the hypothesis that kisspeptin triggering can achieve oocyte maturation while substantially reducing OHSS risk.
The Imperial College group demonstrated successful egg maturation, fertilization, viable embryo production, and pregnancy following kisspeptin-54 triggering in a small cohort of women — establishing proof of concept for the clinical application.
Because kisspeptin-10 retains equivalent receptor agonist activity to kisspeptin-54, this IVF trigger research direction is mechanistically applicable to kisspeptin-10 as a research tool for studying the reproductive axis stimulation pathway used in this approach.
Study 5 — KNDy Pathway and Clinical Translational Implications: Comprehensive Review
Authors: Skorupskaite K, George JT, Anderson RA (University of Edinburgh) Year: 2014 Journal: Human Reproduction Update (PMC) PMID: 24615662 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4063702/
This comprehensive peer-reviewed review from the Human Reproduction Update synthesized the evidence for kisspeptin’s role in human reproductive health, the KNDy pathway biology, and the translational clinical implications — providing the most comprehensive overview of the field available at time of publication.
Kisspeptin signals directly to GnRH neurons through KISS1R to release GnRH into the portal circulation, which in turn stimulates LH and FSH secretion from the anterior pituitary — with the effect on LH being substantially more marked than on FSH.
The KNDy neuron system — co-expressing kisspeptin, neurokinin B, and dynorphin — has been established as the hypothalamic GnRH pulse generator, with kisspeptin constituting the direct output signal from this system to GnRH neurons.
When administered to humans in different isoforms, routes, and doses, kisspeptin robustly stimulates LH secretion and LH pulse frequency — confirming pharmacological utility across multiple kisspeptin variants and delivery approaches in human subjects.
Manipulation of the KNDy system represents active translational research with potential clinical applications in conditions of pathologically low LH pulsatility (hypogonadotropic hypogonadism, hypothalamic amenorrhea, functional hypogonadism) and pathologically high LH pulsatility (polycystic ovary syndrome, where elevated LH pulse frequency is a cardinal feature).
The review highlighted the diagnostic utility of kisspeptin challenge testing: patients with hypothalamic failure (intact GnRH neurons but deficient kisspeptin signaling) respond to kisspeptin administration with LH release, while patients with pituitary gonadotroph failure do not — providing mechanistic diagnostic information unavailable from standard hormone panels.
Kisspeptin-10 vs Kisspeptin-54: Research Tool Considerations
Because kisspeptin-10 and kisspeptin-54 share the identical C-terminal receptor-binding domain, both act as full KISS1R agonists. Their pharmacological differences lie in potency and pharmacokinetics rather than receptor specificity.
Kisspeptin-54 produces greater LH stimulation than kisspeptin-10 at equivalent molar doses in direct human comparisons — likely reflecting the longer plasma half-life of the larger molecule, which produces more sustained receptor activation. Kisspeptin-54 has a plasma half-life of approximately 28 minutes; kisspeptin-10 is cleared more rapidly due to its smaller size, producing a more transient receptor activation profile.
For research applications where a sharp, brief kisspeptin stimulus is required to study pulsatile GnRH dynamics, kisspeptin-10’s rapid clearance may be advantageous. For applications where sustained KISS1R activation is the endpoint — such as the IVF trigger application — kisspeptin-54’s longer duration may be preferred. For cell culture and in vitro receptor biology studies, kisspeptin-10’s smaller size and synthetic accessibility make it the standard research tool.
The KISS1 Gene’s Dual Identity: Metastasis Suppressor and Reproductive Regulator
The KISS1 gene’s dual biological identity — originally characterized as a metastasis suppressor, subsequently revealed as the master reproductive regulator — has generated ongoing research interest in both domains.
In the oncology context, KISS1 and kisspeptin signaling suppress metastatic potential in melanoma, breast cancer, and other tumor types through mechanisms involving reduced matrix metalloproteinase activity, suppressed cell motility and invasion, and inhibition of angiogenesis. This anti-metastatic activity is mechanistically distinct from and pharmacologically separable from the reproductive axis effects.
In the reproductive context, kisspeptin-10 is now established as one of the most potent endogenous activators of the human reproductive axis ever characterized, operating through the obligate upstream control point for GnRH pulsatility.
These two biological roles — metastasis suppression and reproductive activation — coexist in the same molecular scaffold, represent the work of the same gene, and continue to generate active research in both fields.
Current Research Status
Kisspeptin and its isoforms including kisspeptin-10 are not FDA-approved for any therapeutic indication. Active clinical research programs are investigating kisspeptin-54 (the full-length isoform) and longer-acting kisspeptin analogs for IVF oocyte maturation triggering with reduced OHSS risk, hypothalamic amenorrhea, hypogonadotropic hypogonadism, and reproductive diagnostic applications. Kisspeptin-10 is used extensively as a research tool in cell biology, receptor pharmacology, and in vivo HPG axis studies due to its synthetic accessibility and full receptor agonist activity. The broader kisspeptin field — including KNDy pathway pharmacology, neurokinin B receptor antagonism for PCOS, and longer-acting kisspeptin analogs — is one of the most active areas in reproductive neuroendocrinology research.
Reconstitution Note
Kisspeptin-10 is a synthetic decapeptide. Bacteriostatic water is the standard reconstitution solvent. Dissolve gently without vigorous agitation. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Kisspeptin-10 product page: https://roguecompounds.com/product/kisspeptin-10/